Chen Schor
Directeur Général chez ADICET BIO, INC.
Fortune : 163 223 $ au 30/06/2024
Profil
Chen Schor was the founder of resTORbio, Inc. (founded in 2016) and held the title of President, CEO, CFO, Secretary & Director.
He is currently the Chief Executive Officer at Adicet Therapeutics, Inc., President, Chief Executive Officer & Director at Adicet Bio, Inc., Chairman at Carbon Biosciences, Inc., Director at Otic Pharma Ltd., and Director at Alliance for Cancer Gene Therapy, Inc. He is also an Independent Director at Karyopharm Therapeutics, Inc. (since 2020).
Previously, he held positions such as President, Chief Executive Officer & Director at Synta Pharmaceuticals Corp.
(2014-2016), President, Chief Executive Officer & Director at Novalere, Inc., Director at Brainstorm Cell Therapeutics, Inc. (2011-2020), Director at Gelesis, Inc., Director at Cerapedics, Inc., Director at Quiet Therapeutics Ltd., Vice President-Business Development at Teva Pharmaceutical Industries Ltd.
(2009-2011), Chief Business Officer at EPIX Pharmaceuticals, Inc. (2003-2009), Chief Business Officer at Predix Pharmaceuticals, Inc. (2003-2009), VP-Business Development, Global Branded Products at Teva Pharmaceuticals USA, Inc. (2009-2011), Partner at XT Hi-.
Tech Investments (1992) Ltd.
(1998-2003), Principal at Arthur Anderson & Co., Chief Business Officer at Sesen Bio, Inc. (2011-2012), and Partner at Yozma Venture Capital Ltd.
He has an undergraduate degree and an MBA from Tel-Aviv University and an undergraduate degree from the University of Haifa.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ADICET BIO INC
0,16% | 05/06/2024 | 134 895 ( 0,16% ) | 163 223 $ | 30/06/2024 |
| 29/05/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Postes actifs de Chen Schor
| Sociétés | Poste | Début |
|---|---|---|
| ADICET BIO, INC. | Directeur Général | 01/07/2016 |
| KARYOPHARM THERAPEUTICS INC. | Directeur/Membre du Conseil | 25/11/2020 |
Carbon Biosciences, Inc.
 Carbon Biosciences, Inc. Medical/Nursing ServicesHealth Services Carbon Biosciences, Inc. is a biotech company that is based in Boston, MA. The company is focused on expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues and carry a larger cargo with minimal neutralizing immunity and the potential to re-dose. The company is working to expand the gene therapy toolbox for the treatment of the world's most devastating and difficult to treat diseases. Carbon was founded by Longwood Fund and gene therapy pioneers, John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D. | Président | - |
Alliance for Cancer Gene Therapy, Inc.
 Alliance for Cancer Gene Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Alliance for Cancer Gene Therapy, Inc. provides funding for cancer research. The non-profit company is based in Stamford, CT. The company was founded by Edward Netter. Kevin Honeycutt has been the CEO of the company since 2018. | Directeur/Membre du Conseil | - |
Adicet Therapeutics, Inc.
 Adicet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA. | Directeur Général | 15/09/2020 |
Otic Pharma Ltd.
 Otic Pharma Ltd. Pharmaceuticals: MajorHealth Technology Otic Pharma Ltd. develops and manufactures pharmaceutical products for ear indications. Its products include FoamOtic Externa, FoamOtic Sinus, Foam-O-Vet, and FoamOtic Media. The company was founded by Gad Riesenfeld, Rodrigo A. Yelin and Eran Eilat in March 2008 and is headquartered in Irvine, CA. | Directeur/Membre du Conseil | - |
Anciens postes connus de Chen Schor
| Sociétés | Poste | Fin |
|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. | Directeur/Membre du Conseil | 30/03/2020 |
Synta Pharmaceuticals Corp.
 Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Directeur Général | 22/07/2016 |
| CARISMA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/10/2012 |
| ░░░░ ░░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Chen Schor
| Tel-Aviv University | Masters Business Admin |
| University of Haifa | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. | Health Technology |
| ADICET BIO, INC. | Health Technology |
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
| Entreprise privées | 17 |
|---|---|
EPIX Pharmaceuticals, Inc.
 EPIX Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology EPIX Pharmaceuticals, Inc. used to develop targeted contrast agents both to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human disease. The company was founded in 1988 and was headquartered in Lexington, MA. | Health Technology |
Predix Pharmaceuticals, Inc.
 Predix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Predix Pharmaceuticals, Inc. develops novel drugs and other related products. It is a clinical stage drug development company that uses proprietary discovery and lead optimization engine to develop novel drugs for G-protein coupled receptor (GPCR) and ion channel targets. The company was founded by Silvia Noiman, Haim Aviv, Oren M. Becker and Oren M. Ramot in September, 2002 and is headquartered in Woburn, MA. | Health Technology |
Gelesis, Inc.
 Gelesis, Inc. BiotechnologyHealth Technology Gelesis, Inc. operates as a consumer-centered biotherapeutics company, which engages in the development of novel therapies to induce weight loss and metabolic disorders. Its commercial product portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease /Non-alcoholic Steatohepatitis, and Functional Constipation. The company was founded by Yishai Zohar in 2006 and is headquartered in Boston, MA. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Teva Pharmaceuticals USA, Inc.
 Teva Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Teva Pharmaceuticals USA, Inc. engages in the manufacturing and marketing of generic pharmaceuticals. The firm also provides medical affairs, quality plus safety and trade partner services. The company was founded in 1985 and is headquartered in Parsippany, NJ. | Health Technology |
| Arthur Anderson & Co. | |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Health Technology |
Quiet Therapeutics Ltd.
 Quiet Therapeutics Ltd. Medical SpecialtiesHealth Technology Quiet Therapeutics Ltd. develops a proprietary nanoparticle-based delivery system for the targeted delivery of chemotherapy and anti-inflammatory drugs. It developed a class of cancer therapeutics called GAGomers, enables the flexibility of delivering a medicine that can kill the cancer cells and block the production of proteins that promote the cancer. The company was founded by Dan Peer and Rimona Margalit in 2009 and is headquartered in Ness Ziona, Israel. | Health Technology |
Otic Pharma Ltd.
Otic Pharma Ltd. Pharmaceuticals: MajorHealth Technology Otic Pharma Ltd. develops and manufactures pharmaceutical products for ear indications. Its products include FoamOtic Externa, FoamOtic Sinus, Foam-O-Vet, and FoamOtic Media. The company was founded by Gad Riesenfeld, Rodrigo A. Yelin and Eran Eilat in March 2008 and is headquartered in Irvine, CA. | Health Technology |
Novalere, Inc.
 Novalere, Inc. Pharmaceuticals: MajorHealth Technology Novalere, Inc. develops pharmaceutical products. The company is headquartered in Newton, MA. | Health Technology |
Cerapedics, Inc.
 Cerapedics, Inc. Pharmaceuticals: MajorHealth Technology Cerapedics, Inc. engaged in the provision of developing and commercializing novel osteobiologic products. It offers i-FACTOR Bone Graft, an advanced biologic that supported with level I evidence, and provides benefit ratio. The company was founded by Andrew J. Tofe and is headquartered in Westminster, CO. | Health Technology |
| XT Hi- Tech Investments (1992) Ltd. | |
resTORbio, Inc.
 resTORbio, Inc. BiotechnologyHealth Technology resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA. | Health Technology |
Adicet Therapeutics, Inc.
Adicet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA. | Health Technology |
Alliance for Cancer Gene Therapy, Inc.
Alliance for Cancer Gene Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Alliance for Cancer Gene Therapy, Inc. provides funding for cancer research. The non-profit company is based in Stamford, CT. The company was founded by Edward Netter. Kevin Honeycutt has been the CEO of the company since 2018. | Commercial Services |
Carbon Biosciences, Inc.
Carbon Biosciences, Inc. Medical/Nursing ServicesHealth Services Carbon Biosciences, Inc. is a biotech company that is based in Boston, MA. The company is focused on expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues and carry a larger cargo with minimal neutralizing immunity and the potential to re-dose. The company is working to expand the gene therapy toolbox for the treatment of the world's most devastating and difficult to treat diseases. Carbon was founded by Longwood Fund and gene therapy pioneers, John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D. | Health Services |
| Yozma Venture Capital Ltd. | Finance |
